Form 4: Amneal Pharmaceuticals Executive Jason B. Daly Reports Stock Transactions

Jason B. Daly, SVP, Chief Legal Officer of Amneal Pharmaceuticals, reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Summary

• On March 3, 2024, Jason B. Daly, SVP, Chief Legal Officer of Amneal Pharmaceuticals, engaged in transactions involving Class A Common Stock and Restricted Stock Units (RSUs).
• Daly acquired 22,645 and 38,226 shares of Class A Common Stock upon vesting of RSUs.
• Simultaneously, Daly disposed of 7,166 and 10,864 shares of Class A Common Stock to satisfy tax withholding obligations at a price of $5.47 per share.
• Daly was also granted 143,519 restricted stock units and 287,038 performance-based restricted stock units on March 4, 2024.
• Following these transactions, Daly directly owns 57,322 shares of Class A Common Stock, 45,290 Restricted Stock Units, 114,679 Restricted Stock Units and 143,519 Restricted Stock Units and 287,038 Performance-Based Restricted Stock Units.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting stock transactions. The granting of equity can be seen as a positive sign of aligning management with shareholder interests, but the tax-related sales are a neutral event.

Positives

• The granting of restricted stock units and performance-based restricted stock units to a key executive aligns their interests with the long-term success of the company.

Risks

• The vesting of performance-based restricted stock units is contingent on the company's stock price performance, which may not be achieved.

Future Outlook

The vesting of restricted stock units and performance-based restricted stock units in the future is dependent on continued service and, in the case of performance-based units, the company's stock price performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often viewed as a way to align management's interests with those of shareholders. The vesting of RSUs is a standard form of compensation, while performance-based RSUs are used to incentivize executives to achieve specific financial goals.

Comparison to Industry Standards

• Stock-based compensation is a common practice among pharmaceutical companies to attract and retain talent.
• Companies like Teva Pharmaceutical Industries and Mylan (now Viatris) also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and performance metrics associated with these awards vary depending on the company and the specific role of the executive.

Stakeholder Impact

• Shareholders may view the granting of equity to executives as a positive sign of alignment with their interests.
• Employees may be motivated by the fact that executives are incentivized to improve the company's performance.

Key Dates